Although MSI2 was shown to be a dependency of aggressive myeloid leukemias as well as solid cancers such as pancreatic cancer15,17–19, and its transgenic overexpression can lead to increased tumor burden19, whether MSI2 translocations or mutations harbored in patients can serve as oncogenes and driver mutations was unknown. Here, MSI2 is linked to myeloid leukemia.